Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRN OTCMKTS:GNMSF NASDAQ:GRFS OTCMKTS:MKGAF OTCMKTS:UCBJF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$54.090.0%$54.56$49.26▼$66.28$10.45B0.232.16 million shs2.44 million shsGNMSFGenmab A/S$258.12-4.2%$269.72$198.51▼$352.00$15.89B0.825,707 shs3 shsGRFSGrifols$7.98-1.6%$8.05$7.39▼$11.14$5.43B0.68617,819 shs379,991 shsMKGAFMerck KGaA$151.34+1.4%$132.87$116.68▼$159.34$21.87B0.96673 shs1,036 shsUCBJFUCB$270.35-4.2%$295.77$178.54▼$345.39$34.78B0.47793 shs4,139 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%+4.40%+0.20%-15.59%-7.51%GNMSFGenmab A/S0.00%-2.70%-5.04%-9.24%+23.89%GRFSGrifols0.00%+4.18%-0.13%-15.11%-2.56%MKGAFMerck KGaA0.00%+5.91%+15.75%-0.90%+15.99%UCBJFUCB0.00%-6.49%-8.83%-20.07%+53.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$54.090.0%$54.56$49.26▼$66.28$10.45B0.232.16 million shs2.44 million shsGNMSFGenmab A/S$258.12-4.2%$269.72$198.51▼$352.00$15.89B0.825,707 shs3 shsGRFSGrifols$7.98-1.6%$8.05$7.39▼$11.14$5.43B0.68617,819 shs379,991 shsMKGAFMerck KGaA$151.34+1.4%$132.87$116.68▼$159.34$21.87B0.96673 shs1,036 shsUCBJFUCB$270.35-4.2%$295.77$178.54▼$345.39$34.78B0.47793 shs4,139 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%+4.40%+0.20%-15.59%-7.51%GNMSFGenmab A/S0.00%-2.70%-5.04%-9.24%+23.89%GRFSGrifols0.00%+4.18%-0.13%-15.11%-2.56%MKGAFMerck KGaA0.00%+5.91%+15.75%-0.90%+15.99%UCBJFUCB0.00%-6.49%-8.83%-20.07%+53.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRNBioMarin Pharmaceutical 2.75Moderate Buy$88.6763.92% UpsideGNMSFGenmab A/S 0.00N/AN/AN/AGRFSGrifols 1.75Reduce$10.0025.31% UpsideMKGAFMerck KGaA 0.00N/AN/AN/AUCBJFUCB 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest BMRN, GNMSF, MKGAF, GRFS, and UCBJF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026BMRNBioMarin Pharmaceutical Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$116.00 ➝ $111.005/19/2026BMRNBioMarin Pharmaceutical Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$85.00 ➝ $80.005/19/2026BMRNBioMarin Pharmaceutical CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.005/18/2026BMRNBioMarin Pharmaceutical CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/18/2026BMRNBioMarin Pharmaceutical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$55.00 ➝ $50.005/15/2026BMRNBioMarin Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/11/2026BMRNBioMarin Pharmaceutical The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Neutral$69.005/8/2026GRFSGrifols Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/8/2026GRFSGrifols Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/7/2026BMRNBioMarin Pharmaceutical Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$104.00 ➝ $116.005/5/2026BMRNBioMarin Pharmaceutical Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$94.00 ➝ $82.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRNBioMarin Pharmaceutical$3.24B3.22$2.85 per share18.96$32.14 per share1.68GNMSFGenmab A/S$3.72B4.27$14.99 per share17.22$92.29 per share2.80GRFSGrifols$7.44B0.73$1.39 per share5.73$13.49 per share0.59MKGAFMerck KGaA$22.72B0.86$45.58 per share3.32$212.00 per share0.71UCBJFUCB$5.27B9.70$11.61 per share23.28$50.52 per share5.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRNBioMarin Pharmaceutical$348.90M$1.3739.489.690.418.29%6.50%5.07%8/3/2026 (Estimated)GNMSFGenmab A/S$963M$13.2619.47N/AN/A21.05%15.34%8.94%8/6/2026 (Estimated)GRFSGrifols$454.82M$0.1942.005.960.315.54%6.21%2.39%7/23/2026 (Estimated)MKGAFMerck KGaA$3.06B$6.8123.1114.35N/A12.60%10.17%5.74%8/6/2026 (Estimated)UCBJFUCB$371.23MN/AN/A38.29N/AN/AN/AN/A7/30/2026 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/AGNMSFGenmab A/SN/AN/AN/AN/AN/AGRFSGrifols$0.141.75%N/A73.68%N/AMKGAFMerck KGaAN/AN/AN/AN/AN/AUCBJFUCBN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRNBioMarin Pharmaceutical0.235.814.20GNMSFGenmab A/S0.872.182.17GRFSGrifols1.162.470.85MKGAFMerck KGaA0.271.310.84UCBJFUCB0.331.190.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRNBioMarin Pharmaceutical98.71%GNMSFGenmab A/SN/AGRFSGrifolsN/AMKGAFMerck KGaA0.10%UCBJFUCBN/AInsider OwnershipCompanyInsider OwnershipBMRNBioMarin Pharmaceutical0.85%GNMSFGenmab A/S1.54%GRFSGrifols0.19%MKGAFMerck KGaAN/AUCBJFUCBN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRNBioMarin Pharmaceutical3,221193.28 million191.64 millionOptionableGNMSFGenmab A/S3,02961.57 million60.62 millionNot OptionableGRFSGrifols25,247680.58 million679.28 millionOptionableMKGAFMerck KGaA62,908129.24 millionN/ANot OptionableUCBJFUCB9,083189.02 millionN/ANot OptionableGRFS, MKGAF, UCBJF, BMRN, and GNMSF HeadlinesRecent News About These CompaniesUCB SA (OTCMKTS:UCBJF) Given Average Recommendation of "Buy" by BrokeragesMay 14, 2026 | americanbankingnews.comUCB SA (OTCMKTS:UCBJF) Receives Average Recommendation of "Buy" from AnalystsMay 9, 2026 | marketbeat.comBelgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billionMay 3, 2026 | reuters.comUCB (OTCMKTS:UCBJF) Shares Gap Down - Here's WhyApril 29, 2026 | marketbeat.comBelgian pharma UCB to buy U.S.-based Neurona for up to $1.15BApril 17, 2026 | seekingalpha.comBelgium's UCB in autoimmune drug deal with AntengeneMarch 3, 2026 | reuters.comDay by Day maintains UCB (UCBJF) buy recommendationDecember 17, 2025 | msn.comUCB price target raised to EUR 300 from EUR 230 at JPMorganDecember 8, 2025 | msn.comUCB removed from European Conviction List at Goldman SachsNovember 4, 2025 | msn.comUCB assumed with an Underperform at JefferiesOctober 27, 2025 | msn.comUCB announces new three-year data from Phase 3 trials on BIMZELXOctober 26, 2025 | msn.comUnited Community Banks, Inc. (UCB) Q3 2025 Earnings Call TranscriptOctober 22, 2025 | seekingalpha.comUCB price target raised to EUR 290 from EUR 220 at BerenbergOctober 14, 2025 | msn.comUCB price target raised to EUR 285 from EUR 250 at Deutsche BankOctober 6, 2025 | msn.comMoonLake rebounds despite downgrades prompted by trial setbackSeptember 30, 2025 | msn.comUCB price target raised to EUR 240 from EUR 220 at Morgan StanleySeptember 8, 2025 | msn.comUCB SA (UCBJF) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | seekingalpha.comUnited Community Banks, Inc. (UCB) Q2 2025 Earnings Call TranscriptJuly 23, 2025 | seekingalpha.comUCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life SciencesMay 20, 2025 | finance.yahoo.comUnited Community Banks, Inc. (UCB) Q1 2025 Earnings Call TranscriptApril 22, 2025 | seekingalpha.comUCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025April 3, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRFS, MKGAF, UCBJF, BMRN, and GNMSF Company DescriptionsBioMarin Pharmaceutical NASDAQ:BMRN$54.09 -0.01 (-0.02%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$54.08 -0.02 (-0.03%) As of 05/22/2026 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Genmab A/S OTCMKTS:GNMSF$258.12 -11.38 (-4.22%) As of 05/22/2026 09:30 AM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Grifols NASDAQ:GRFS$7.98 -0.13 (-1.60%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.92 -0.06 (-0.69%) As of 05/22/2026 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.Merck KGaA OTCMKTS:MKGAF$151.34 +2.13 (+1.43%) As of 05/22/2026 03:54 PM EasternMerck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.UCB OTCMKTS:UCBJF$270.35 -11.90 (-4.22%) As of 05/22/2026 12:05 PM EasternUCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
